F Sellebjerg
Overview
Explore the profile of F Sellebjerg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
1847
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ammitzboll C, Dyrby T, Lyksborg M, Schreiber K, Ratzer R, Romme Christensen J, et al.
Mult Scler Relat Disord
. 2018 Jan;
20:73-77.
PMID: 29324249
Background: Progressive multiple sclerosis (MS) is characterised by diffuse changes on brain magnetic resonance imaging (MRI), which complicates the use of MRI as a diagnostic and prognostic marker. The relationship...
12.
Olsson A, Oturai A, Sondergaard H, Sellebjerg F, Oturai P
Acta Neurol Scand
. 2017 Dec;
137(3):363-369.
PMID: 29270986
Background: Multiple sclerosis (MS) patients are at increased risk of reduced bone mineral density (BMD) and fractures. The aetiology of bone loss in MS is unclear. Trabecular bone score (TBS)...
13.
Petersen E, Sondergaard H, Oturai A, Jensen P, Sorensen P, Sellebjerg F, et al.
Mult Scler Relat Disord
. 2016 Dec;
10:66-72.
PMID: 27919501
Background: Natalizumab reduces disease activity in multiple sclerosis (MS). Natalizumab binds to the very late antigen-4 and inhibits vascular cell adhesion molecule-1 (VCAM-1)-mediated transmigration of immune cells across the blood-brain-barrier....
14.
Voldsgaard A, Koch-Henriksen N, Magyari M, Sellebjerg F, Sorensen P, Oturai A
Acta Neurol Scand
. 2016 Dec;
135(1):129-133.
PMID: 27910101
Background: Initiation of fingolimod treatment is associated with a transient decrease of heart rate, and atrioventricular (AV) conduction block may occur. Objective: To evaluate the therapeutic effect and safety of...
15.
Gustavsen S, Sondergaard H, Oturai D, Laursen B, Laursen J, Magyari M, et al.
Mult Scler Relat Disord
. 2016 Sep;
9:104-9.
PMID: 27645354
Background: Epidemiological studies suggest an important role for environmental factors in developing multiple sclerosis (MS). Furthermore several studies have indicated that the effect of environmental factors may be especially pronounced...
16.
Mollgaard M, Degn M, Sellebjerg F, Frederiksen J, Modvig S
Eur J Neurol
. 2016 Feb;
23(5):898-905.
PMID: 26872061
Background And Purpose: The role of chitinases and chitinase-like proteins in multiple sclerosis (MS) is currently unknown; however, cerebrospinal fluid (CSF) levels of chitinase 3-like 1 (CHI3L1) predict prognosis in...
17.
Sorensen P, Sellebjerg F, Lycke J, Farkkila M, Creange A, Lund C, et al.
Eur J Neurol
. 2016 Feb;
23(5):861-70.
PMID: 26848561
Background And Purpose: Combining different therapies may improve disease control in patients with relapsing-remitting multiple sclerosis (RRMS). This study assessed the efficacy and safety of minocycline added to subcutaneous (sc)...
18.
Dreyer L, Magyari M, Laursen B, Cordtz R, Sellebjerg F, Locht H
Ann Rheum Dis
. 2015 Dec;
75(4):785-6.
PMID: 26698850
No abstract available.
19.
Oturai D, Sondergaard H, Bornsen L, Sellebjerg F, Romme Christensen J
Scand J Immunol
. 2015 Sep;
83(1):72-80.
PMID: 26395032
Quantitative real-time PCR (qPCR) involves the need of a proper standard for normalizing the gene expression data. Different studies have shown the validity of reference genes to vary greatly depending...
20.
Modvig S, Degn M, Sander B, Horwitz H, Wanscher B, Sellebjerg F, et al.
Mult Scler
. 2015 Aug;
22(5):590-8.
PMID: 26283696
Background: Optic neuritis is a good model for multiple sclerosis relapse, but currently no tests can accurately predict visual outcome. Objective: The purpose of this study was to examine whether...